Analysis of the assortment, socio-economic availability and volumes of drugs consumption of the nonsteroidal anti-inflammatory group on the Ukrainian pharmaceutical market
DOI:
https://doi.org/10.24959/uekj.19.26Keywords:
NSAIDs, analysis of assortment in Ukraine, availability of drugs, consumption by ATC/DDD-methodologyAbstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the world and in Ukraine. Anti-inflammatory and analgesic therapy of chronic musculoskeletal system diseases should be conducted for long periods of time. This requires the presence of NSAIDs that are characterized by distinct pharmacological properties and a high level of safety.
Aim. To study the assortment, economic availability and volumes of NSAIDs consumption on the pharmaceutical market of Ukraine during the period of 2014-2018.
Materials and methods. Data of the information and retrieval system “Morion” were used to analyze the assortment of NSAIDs. To analyze the availability of NSAIDs, the solvency adequacy ratio of Ca.s. was calculated, which means % of the average salary needed to pay for a monthly course of treatment with a certain drug. Consumption of drugs was carried out using the ATC / DDD methodology, which is a tool for determining the number of prescribed and taken for a specific time period daily doses of drugs (DDD) with a specific ATC code, which defines indications for use. Results were reported in standardized international units of DDDs/1000 inhabitants/day (DiD).
Results. Studies have shown that NSAIDs on the pharmaceutical market are represented by 32 INN and 302-419 trade names (TNs). Most of the drugs are represented by foreign manufacturers. Ukrainian
pharmaceutical companies presented 37 % of TN in 2018. The following INNs were presented during the study period by the largest number TN: Diclofenac (69-80), Ketorolac (14-18), Diclofenac Combinations (13-20), Meloxicam (52-66), Ibuprofen (58-66), Dexketoprofen (17-24), Nimesulide (21-25), Chondroitin sulfate (18-22). From 75 % to 86 % of TN on the market had high availability for the population in 2014-2018, from 3 to 4 % of TN – low availability. The volume of NSAID consumption use in Ukraine during 2014-2018 was significant: in 2014 – 16.67 DiD; in 2015 – 14.67 DiD; at 2016 – 16.37 DiD; in 2017 – 18.5 DiD; in 2018 – 20.4 DiD. The following drugs were most consumed in all five years of study: Diclofenac, Nimesulide, Ibuprofen, Ketorolac, Meloxicam. Among them, only Ibuprofen is a non-prescription drug and used in pediatrics as an antipyretic and analgesic drug. These are the INN that are on the Ukrainian market with the greatest number of TNs and that have advantages in terms of their pharmacological action and safety with long-term use for the treatment of chronic diseases.
Conclusions. On the pharmaceutical market of Ukraine wide assortment of INN and TNs of NSAIDs are represented, consumed in large volumes, increasing every year. Among them, a large segment of TN based on five INN (Diclofenac, Nimesulide, Ibuprofen, Ketorolac and Meloxicam), which have marked clinical efficacy and are safe for long-term use, are the most consumed.
References
He, B., Wang, J., Liu, J., & Hu, X. (2017). Eco-pharmacovigilance of non-steroidal anti-inflammatory drugs: Necessity and opportunities. Chemosphere, 181, 178–189. https://doi.org/10.1016/j.chemosphere.2017.04.084
Brune, & Patrignani, P. (2015). New insights into the use of currently available non-steroidal anti-inflammatory drugs. Journal of Pain Research, 105. https://doi.org/10.2147/jpr.s75160
Badri, W., Miladi, K., Nazari, Q. A., Greige-Gerges, H., Fessi, H., & Elaissari, A. (2016). Encapsulation of NSAIDs for inflammation management: Overview, progress, challenges and prospects. International Journal of Pharmaceutics, 515(1-2), 757–773. https://doi.org/10.1016/j.ijpharm.2016.11.002
Bjarnason, I. (2012). Gastrointestinal safety of NSAIDs and over-the-counter analgesics. International Journal of Clinical Practice, 67, 37–42. https://doi.org/10.1111/ijcp.12048
Goldstein, J., & Cryer, B. (2015). Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug, Healthcare and Patient Safety, 31. https://doi.org/10.2147/dhps.s71976
Gómez-Acebo, I., Dierssen-Sotos, T., de Pedro, M., Pérez-Gómez, B., Castaño-Vinyals, G., Fernández-Villa, T., … Llorca, J. (2018). Epidemiology of non-steroidal anti-inflammatory drugs consumption in Spain. The MCC-Spain study. BMC Public Health, 18(1). https://doi.org/10.1186/s12889-018-6019-z
Kotvitska, A. A., Kostyuk, V. G. (2016). Farmatsevtychnyi chasopys, 2, 48–53. https://doi.org/10.11603/2312-0967.2016.2.6651
Iakovlieva, L. V., Titova, A. A. (2019). Farmakoekonomika v Ukraini: stan ta perspektyvy rozvytku: materialy XI naukovo-praktychnoi Internet-konferentsii. Kharkiv: NFaU, 210–213.
WHO Collaboratind Centre for Drug Statistics Methodology. (n.d). Available at: https://www.whocc.no/atc_ddd_index/
Derzhavna sluzhba statystyky Ukrayiny. (n.d.). Available at: www.ukrstat.gov.ua
Dovidnyk «Kompendium 2015». (2015). Available at: https://compendium.com.ua/uk/
Gappe, N. A. (2013). Ukraїns’kiĭ medichniĭ chasopis, 3, 115–117.
Morozova, T. E., Andrushishina, T. B., Antipova, E. K. (2013). Terapevticheskiĭ arkhiv, 85 (3), 118–124.
Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorovia Ukrainy. (n.d.). «Derzhavnyi reiestr likarskykh zasobiv Ukrainy». http://www.drlz.com.ua
Morozov, A. M. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATS/DDD-metodolohiia): metod. rek. Kharkiv: Styl-Izdat, 34.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
